The present invention relates to medical methods and systems for treating chronic obstructive pulmonary disease (COPD), and more specifically to methods and systems for assisting a physician determine optimal treatment modalities to perform lung volume reduction on a patient with COPD.
COPD is a chronic disease of the lungs, in which the destruction of the inner lung structure makes breathing increasingly difficult. While symptoms include shortness of breath, excessive production of sputum, and coughing, many people do not experience any symptoms until the later stages of the disease. There are currently many treatment options for COPD but there is no cure, nor a universal standard.
One treatment option for COPD not manageable by systemic delivery of medication is lung volume reduction. Lung Volume reduction is the removal or collapse of damaged lung tissue, thereby allowing the remaining healthy tissue to expand.
Various treatment modalities are available to perform lung volume reduction including vapor ablation, installation of valves or coils, and application of sealant.
However, it is difficult to determine which treatment modality is best because one treatment modality may be more compatible with a particular patient than another treatment modality based on a various patient factors or characteristics. Additionally, a physician may prefer one type of treatment modality over another in view of her experience, skill, and training relating to the various treatment modalities as well as local availability and reimbursement.
Accordingly, a system and method that overcomes the above mentioned challenges is desirable.
The present invention is a method and system for assisting a physician to determine an optimal treatment modality for performing lung volume reduction on a patient.
In embodiments, a computer-implemented method provides a plurality of primary categories of disease attributes amongst COPD patients. A physician preference input is received for at least one of the disease attributes. An output corresponding to an optimal treatment modality is determined. The output is based on the physician preference inputs and diagnostic information relating to a patient or group of patients.
In embodiments, the primary categories of disease attributes include disease heterogeneity, segmental or lobar treatment, fissure integrity, maximum destruction criteria, residual volume, and desired treatment locations.
In embodiments, the method additionally provides a choice of sub or minor categories for each primary category. Heterogeneity, for example, has two sub categories, including Lobar Heterogeneity and Segmental Heterogeneity. Regarding Lobar Heterogeneity, the physician enters the threshold ratio in the disease severity that represents a significant difference between two lobes of the lung. Additionally, in embodiments, the physician can select what represents a significant disease difference in two segments of lung.
In embodiments, a primary category or disease attribute is BLVR approach. If segments within a lobe is heterogeneously diseased, then a segmental treatment approach is often preferred to preserve relatively healthy tissue. If a lobe contains equally diseased segments, or homogeneous lobe, then a lobar treatment approach is often preferred. The physician selects whether lobar or segmental approach is preferred. In embodiments, the physician also selects whether a unilateral or bilateral approach is preferred.
In embodiments, a primary category or disease attribute is fissure integrity or completeness criteria. Fissure integrity score is a strong predictor of the presence of collateral ventilation. Blocking technologies such as valves are known to be ineffective in patients with collateral ventilation. The physician chooses a fissure integrity criteria that quantifies or sets a threshold for collateral ventilation. The system allows the physician to qualify or disqualify certain Lung Volume Reduction technologies such as valve-based programs if the fissure integrity score is too low.
In embodiments, the physician selects the maximum percentage of destroyed lobes considered treatable. Mechanical BLVR technologies such as coils cannot effectively hold down tissue to reduce lung volume if the tissue in the diseased region is largely destroyed.
In one embodiment, if the degree of destruction in the patient(s) lobes from the patient data is higher than the physician's input, certain technologies such as coils are automatically excluded, or lowered in score, and ranking.
In embodiments, data is received corresponding to a specific patient, or group of specific patients, and output is determined in the form of an optimal treatment modality for that patient or patient group. The output is determined based on the physician's preferences and the diagnostic information for the patient(s).
In embodiments, a database of patient data based on the demographics of the physician's typical COPD patients is received, and an output is determined and displayed in the form of one or more charts. In embodiments, the percentage of patients within the recommended treatment modalities is displayed. As described herein, determination of the recommended modalities and percentage of patients within each modality is based on the physician's preference criteria as well as the patient(s) data.
In embodiments, a system for assisting a physician perform a lung volume reduction procedure on a patient comprises a processor operable to: (i) compute disease characteristics for bronchial segments, lung lobes, and lung fissures of the patient based on lung image information of the patient; and (ii) transform the lung image information into a non-anatomical shaped graphic indicative of the relative volume and disease characteristics of the bronchial segments, lung lobes, and fissures of the patient; and a display in communication with the processor and operable to present the graphic.
In embodiments, a method for assisting a physician perform a lung volume reduction procedure on a patient comprises computing disease characteristics for bronchial segments, lung lobes, and lung fissures of the patient based on received lung image information of the patient; computing a non-anatomical shaped graphic indicative of the relative volume of the bronchial segments and lung lobes, and disease characteristics corresponding to the bronchial segments and the lung lobes of the patient; and displaying the graphic.
In embodiments, the step of computing the graphic is performed by transforming the image information of the patient's bronchial segments and lung lobes into the non-anatomical shaped graphic.
In embodiments, the transforming comprises converting the lung image data for each lung into a donut-shaped graphic for each lung.
In embodiments, each donut-shaped graphic comprises an inner ring and an outer ring, and wherein each inner and outer ring comprises a plurality of arcuate segments corresponding to the relative volume of the lung lobe and bronchial segments, respectively.
In embodiments, the method further comprises determining a treatment modality based on the lung image information and a physician preference input.
In embodiments, the method further comprises treating the lung with an interventional appliance corresponding to said treatment modality from the determining step.
Still other descriptions, objects and advantages of the present invention will become apparent from the detailed description to follow, together with the accompanying drawings.
Before the present invention is described in detail, it is to be understood that this invention is not limited to particular variations set forth herein as various changes or modifications may be made to the invention described and equivalents may be substituted without departing from the spirit and scope of the invention. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s) to the objective(s), spirit or scope of the present invention. All such modifications are intended to be within the scope of the claims made herein.
Methods recited herein may be carried out in any order of the recited events which is logically possible, as well as the recited order of events. Furthermore, where a range of values is provided, it is understood that every intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein.
All existing subject matter mentioned herein (e.g., publications, patents, patent applications and hardware) is incorporated by reference herein in its entirety except insofar as the subject matter may conflict with that of the present invention (in which case what is present herein shall prevail).
The following patents and applications are incorporated herein by reference in their entirety: U.S. Pat. Nos. 7,913,698; 8,585,645; 7,993,323; and U.S. Pat. Nos. 8,147,532; 8,734,380; and US Patent Publication No. 2015/0094607.
Reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
System Overview
System 10 is also shown comprising a database 40 of diagnostic information for one or more patients. The database may be stored locally, or on a remote server and linked to the processor through a wired, or wireless interface. Examples of diagnostic information include, without limitation, pulmonary function tests, diffusing capacity, perfusion, and results of CT quantitative analyses (fissure integrity, tissue volume, tissue density, disease severity).
System 10 is also shown including a display 50. Examples of displays include, without limitation, computer monitors, smart phone, tablet or PDA displays, etc. In embodiments, the input and output functionality are combined on a single touch screen display.
System 10 may be in the form of a desktop computer, laptop, tablet, smart phone, PDA or other apparatus and is only intended to be limited to a particular housing or configuration where recited in the appended claims.
Method Overview
Step 110 states to provide a plurality of main categories of disease attributes. As described herein, various disease attributes may be displayed in a drop-down menu to the physician. Examples of disease attributes include, without limitation, heterogeneity, treatment location, treatment approach, maximum tissue destruction, and fissure integrity.
Step 120 states to receive the physician input. As described herein, a physician may input a preference input for each disease attribute described above.
Step 130 states to determine output corresponding to treatment modalities. In embodiments, and as described further herein, step 130 determines an optimal treatment modality or ranking of treatment modalities for one or more patient(s).
In embodiments, step 130 determines optimal treatment modalities for a percentage of patients based on the physician preference input for the disease attributes (main categories, and in some embodiments, sub-categories), and the patient data from the group of patients. As described herein the patient data may be entered by the physician, or received from an inter-connected electronic database of group data of patients. In embodiments, the physician enters the patient data.
Step 140 states to display output of the treatment modality. Output, as described herein, may displayed on a monitor or tablet device. Examples of output may include a preferred treatment modality, ranking, scores, or percentages of treatment modalities. In one embodiment, the output includes a ranking of modalities selected from the group consisting of vapor ablation, valves, coils, and DNQ (does not qualify or no LVR-type treatment).
Heterogeneity
With reference to lobar heterogeneity 312, the physician enters the percent difference in the tissue density (e.g., without limitation, tissue to air ratio, mean lung density, and LAA %) that, in her view, represents a significant difference between two given lobes of the lung.
With reference to segmental heterogeneity 314, a drop-down menu or list of candidate inputs 318 is shown. The physician can select a significant density ratio 316 representing the density difference in two given segments of lung. In embodiments, the candidate inputs for segmental heterogeneity are density differences in the range of 10 to 30%.
In embodiments, instead of candidate inputs, the physician is prompted to enter any threshold value or amount. For example, a question or blank space is shown for the physician to respond to by entering the threshold value, percent, or amount.
Without intending to be bound by theory, one type of treatment may be excluded or preferred if there is a significant difference between the heterogeneity of the lobes or segments as described herein. For example, for highly heterogenous segments, a vapor ablation treatment may be preferred because a vapor ablation treatment can be segment specific. In contrast, valves are not segment specific because valves reduce an entire anatomy portion.
After the physician provides her preference input and the patient data is received, an optimal treatment modality is calculated using the physician inputs as thresholds to rank or exclude certain treatment modalities.
Treatment Approach
Without intending to be bound by theory, if segments within a lobe are heterogeneously diseased, then a segmental treatment approach is preferred. However, if a lobe contains equally diseased segments, or a homogeneous lobe, then a lobar treatment approach is acceptable. The physician selects a lobar or segmental approach. Additionally, in embodiments, the physician selects whether a unilateral or bilateral approach is preferred.
Fissure Integrity
Without intending to be bound by theory, fissure integrity score is a strong predictor of the presence of collateral ventilation. Lower fissure integrity is predictive of higher collateral ventilation. Blocking technologies such as valves are known to be ineffective in patients with high collateral ventilation. The physician chooses a fissure integrity criteria corresponding to a threshold value for collateral ventilation. The system allows the physician to qualify or disqualify certain technologies such as valve-based programs based on the level of collateral ventilation.
In embodiments, the preference input 518 is fissure integrity having a threshold value of at least 80%, 90%, and in some instances about 100%. A patient or group of patients having fissure integrity below this threshold value would be excluded from certain treatment modalities such as valves.
Maximum Destruction
In embodiments, the physician selects the maximum percentage of destroyed lobes that they consider treatable.
Without intending to be bound by theory, mechanical BLVR technologies such as coils cannot effectively hold down tissue to reduce lung volume if the tissue in the diseased region is largely destroyed. In embodiments, the preference input is a maximum destruction criteria having a threshold value in the range from 60 to 80%. A patient or group of patients having tissue destruction above this threshold value would be excluded from certain treatment modalities such as coils.
Treatment Location
Without intending to be bound by theory, some locations may be too remote or difficult to reach for one physician or may not be approved for commercial use in a particular country, jurisdiction, or territory. In embodiments, a preference input is treatment location of the upper lobes only, outside of which certain technologies are excluded such as, e.g., vapor, which at the time of this filing only has approval for use in upper lobes in certain territories.
In embodiments, and although not shown, the output may include solely one modality as an optimal modality for a patient or group of patients based on the patient data and the inputs described herein. The output may be computed and shown as a listing, text line, text box, bar, or pie chart showing a score, percentage, icon, symbol, or color to indicate preference. Indeed, a wide range of text, data, results, and graphics may be displayed.
Physician inputs and patient data may also be graphically displayed as illustrated by the several charts 920. For example, the heterogeneity of the upper left lobe is shown in pie chart form 922 for the group of patients. In the embodiment illustrated in
Data relating to both lungs operating together as a whole is shown in pie charts 930.
The patient data may be graphically displayed in a wide variety of ways. With reference to
Step 1010 states to receive lung model information for a patient. Examples of lung model information include without limitation, various diagnostic information such as pulmonary function tests, diffusing capacity, perfusion, and image data such as CT image data.
Step 1020 states to compute disease characteristics for individual bronchial segments and lobes of the patient based on the receiving step, including fissure integrity, tissue volume, tissue density, disease severity. In embodiments, the disease severity is computed by correlating the voxel density with the disease, and higher density representing the higher presence of the emphysema. Additional examples of methods for determining disease severity are described in US Patent Publication No. 20120249546, and U.S. Pat. Nos. 9,390,498 and 9,504,529.
Step 1030 states to compute a graphic indicative of the bronchial segments, lobes, and the disease characteristics corresponding to the individual segments and lobes. An example of a graphic 1100 is shown in
Step 1040 states to display the graph. As described above, the step of displaying may be performed using a monitor, tablet, PDA, smart phone, screen, etc.
Chart 1110 is representative of the right lung of a patient. Chart 1120 is representative of the left lung. Inner rings 1112, 1122 represent the lobes and outer rings 1114, 1124 represent the bronchial segments. The size of each segment or lobe shown in the rings corresponds to the relative volume of each segment or lobe in the lung of the patient.
With reference to legend 1130, relative shading of each segment or lobe corresponds to the disease severity. The darker the shading, the more severe the disease. Although shading is shown, the invention is not so limited. A wide range of colors, patterns, and/or other indicia may be provided to show disease severity.
Fissure integrity is also indicated by the presence of a break in the rings 1116, 1126, and the degree or completeness of the fissures or separation is indicated by the pattern or color shown in this break in the rings. The more complete the fissure, e.g., the break is shown as more full or nearly completely shaded. In contrast, the less complete the fissure, the break 1112, is shown partially full. Although shading is shown to fill the break, the invention is not so limited. A wide range of colors, patterns, and/or other indicia may be provided to show fissure completeness.
An advantage of one or more of the embodiments described herein is the improvement to the field of bronchoscopy, and more specifically, to BLVR. Bronchoscopy and BLVR are improved in meaningful ways because multiple diagnostic and physician preferences enable a physician to choose, restrict, rank and score various BLVR modalities for various patient population in an automatic, rigorous, consistent, and fast in real time manner based on patient quantifiable phenotype. This is a substantial improvement over previous techniques to eye-ball, gut-feeling, or speculation to which modality may be optimal. In accordance with embodiments discussed herein diagnostic data from multiple patients is applied and cross-examined with an individual physician for increased accuracy. It is anticipated that patient outcomes shall be improved with the present invention.
Although several embodiments have been disclosed above, it is to be understood that other modifications and variations can be made to the disclosed embodiments without departing from the subject invention. The invention includes any method, system, or apparatus for assisting a physician determine an optimal treatment modality for LVR, described herein, or any combination of features and steps described herein for determining an optimal treatment modality for LVR, described herein.
This application is a continuation in part application of patent application Ser. No. 15/927,349, filed Mar. 21, 2018, entitled “SYSTEM FOR DETERMINING OPTIMAL TREATMENT MODALITY FOR LUNG VOLUME REDUCTION AND RELATED METHODS”, which claims benefit of provisional patent application No. 62/475,074, filed Mar. 22, 2017, entitled “SYSTEM FOR DETERMINING OPTIMAL TREATMENT MODALITY FOR LUNG VOLUME REDUCTION AND RELATED METHODS”.
Number | Date | Country | |
---|---|---|---|
62475074 | Mar 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15927349 | Mar 2018 | US |
Child | 16129373 | US |